Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

William Bellamy

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPathology, College of Medicine
DivisionPathology Clinical
Address7S23 Shorey
4104 Outpatient Circle
Mail Slot # 517
Little Rock AR 72205
Phone501-686-8697
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentGenetics, College of Medicine


    Collapse Research Funds 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Dunn ALJ, Gardner JM, Kaley JR, Bellamy W, Shalin SC. ALK Rearrangements Are Infrequent in Cellular Blue Nevus and Deep Penetrating Nevus. Am J Dermatopathol. 2018 Jul; 40(7):469-478. PMID: 29923908.
      View in: PubMed
    2. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    3. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285; PMCID: PMC4352951.
    4. Apewokin S, Vyas K, Lester LK, Grazzuitti M, Haselow DT, Wolfe F, Roberts M, Bellamy W, Kumar NS, Hunter D, Lee J, Laudadio J, Wheeler JG, Bradsher R. Influenza a outbreak in an ambulatory stem cell transplant center. Open Forum Infect Dis. 2014 Sep; 1(2):ofu050. PMID: 25734122; PMCID: PMC4281787.
    5. Groshong AM, Fortune DE, Moore BP, Spencer HJ, Skinner RA, Bellamy WT, Blevins JS. BB0238, a presumed tetratricopeptide repeat-containing protein, is required during Borrelia burgdorferi mammalian infection. Infect Immun. 2014 Oct; 82(10):4292-306. PMID: 25069985; PMCID: PMC4187884.
    6. Beenken KE, Smith JK, Skinner RA, Mclaren SG, Bellamy W, Gruenwald MJ, Spencer HJ, Jennings JA, Haggard WO, Smeltzer MS. Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis. J Biomater Appl. 2014 Oct; 29(4):514-23. PMID: 24854984; PMCID: PMC4264383.
    7. Beenken KE, Bradney L, Bellamy W, Skinner RA, McLaren SG, Gruenwald MJ, Spencer HJ, Smith JK, Haggard WO, Smeltzer MS. Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis. Antimicrob Agents Chemother. 2012 Nov; 56(11):5839-44. PMID: 22948866; PMCID: PMC3486578.
    8. Brown TL, Spencer HJ, Beenken KE, Alpe TL, Bartel TB, Bellamy W, Gruenwald JM, Skinner RA, McLaren SG, Smeltzer MS. Evaluation of dynamic [18F]-FDG-PET imaging for the detection of acute post-surgical bone infection. PLoS One. 2012; 7(7):e41863. PMID: 22860021; PMCID: PMC3408436.
    9. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012 Sep; 97(9):1348-56. PMID: 22419581; PMCID: PMC3436235.
    10. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. PMID: 21517811; PMCID: PMC3272081.
    11. Brown T, Spencer H, Beenken K, Alpe T, Batrtel T, Bellamy W, Gruenwald J, Skinner R, McLaren S, Smeltzer M. "Efficacy of dynamic [18F]-FDG-PET imaging for distinguishing acute osteomyelitis from acute post-surgical inflammation in rabbit model of Staph. aureus infection". Society of Nuclear Medicine 58th Annual San Antonio. 2011.
    12. Korourian S, Lafond-Shank L, Salih Z, Priest J, Bellamy W. "Detection of Her-2 Neu gene expression in cytological specimen". USCAP 100th Annual Meeting. 2011.
    13. Stopek AT, Unger J, Bellamy W, Rimsza L, Iannone M, Persky DO, Fisher RI, Miller TP. APhase II Trial of Single Agent Bevacizumab in Patients with Relapsed, Aggressive Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0108. 2009.
    14. Stopek, AT, Unger, J, Bellamy W, Rimsza, L, Iannone, M, Persky, DO, Fisher, RI, Miller, TP. A Phase II Trial of Single Agent Bevacizumab in Patients with Relapsed, Agressive Non-Hodgkin Lymphoma: Southwest Oncology Group Study SO108. Leukemia & Lymphoma. 2009; (50):728-735.
    15. Cetin N, Bellamy W, Santra M, Barlogie B. "IgM plasma cell myeloma:Clinicopathologic characterization of a rare entity". Laboratory Investigation. 2009; 89:256-7.
    16. Cetin N, Bansal I, Bellamy W, Santra M, Barlogie B, Lorsbach R. IgM plasma cell myeloma: Clinicopathologic characterization of rare entity. Laboratory Investigation. 2009.
    17. Santra M, Shaughnessy J, William DR, Barlogie B, Bellamy WT. Expression of myeloma-specific markers in bone marrow spiclules using a novel immunohistochemical technique. Blood. 2008; 112: 5152a.
    18. Sharma S, Sawyer J, Bellamy W, Lorsbach R, Singh Z N. "Morphological spectrum of non-Burkitt lymphomas with MYC-associated abnormalities". Arch Pathol Lab Med. 2008; 132: 1465.
    19. Sharma S, Sawyer J, Bellamy WT, Lorsbach R, Oza K, Singh ZN. Morphological spectrum of non-Burkitt lymphomas with MYC-associated abnormalities. Arch Pathol Lab Med. 2008; 132:1465.
    20. Zarineh A, Smoller B, Hiatt K, Bellamy WT, Santra M. Cutaneous lesions of multiple myeloma are associated with Epstein-Barr virus, but not human herpesvirus 8. 2008.
    21. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007 Aug; 12(2):115-30. PMID: 17692804.
      View in: PubMed
    22. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006; 13 Suppl:4 - 11.
    23. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006 Dec; 13 Suppl:4-11. PMID: 17242661.
      View in: PubMed
    24. Baker AF, Bellamy W, Tate WR, Bair WB, Heaton R, List AF. Suppressor of cytokine signaling-3 is overexpressed in erythroid precursors of myelodysplastic syndrome. Leukemia. 2006; 20(9):1620 - 1621.
    25. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006; 30(7):801 - 811.
    26. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. PMID: 16332390.
      View in: PubMed
    27. Bellamy W. Textbook of Malignant Haematology. Angiogenesis and Tumor Development. 2005.
    28. Somlo G, Bellamy W, Zimmerman T M, Frankel P, Tuscano J, O'Donnell M, Morbacher A, Forman S, Chen H, Doroshow J, Gandara D. "Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma". Blood. 2005; 106:723A.
    29. Stopek A T, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher R I, Miller T P. "Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma: southwest Oncology Group Study S0108". J Clin Oncolog. 2005; 23:6592.
    30. List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol. 2004; 32(6):526 - 535.
    31. Baker A F, Bellamy W, Tate W R, Bair W, Glinsmann-Gibson B J, Heaton R, List A. "Suppressor of cytokine signaling 3 protein (SOCS-3) is up-regulated in myelodysplastic syndrome". Proc Amer Assoc Cancer Res. 2004; 45: 1169.
    32. Milojkovic D, Sahu S, Henderson J, Czepulkowsi B H, Salisbury J R, Bellamy W, Devereaux S, Pagliuca A, Ho A Y L, Mufti G J. "Immunohistochemical characterization of vascular endothelial growth factor (FEGF) and its receptors Flt-1 and KDR in chronic myeloid Leukaemia (CML) patients treated with Imatinib Mesylate". Blood. 2004; 104:551A.
    33. Giles F J, Steinfeldt H, Bellamy W, Bycott P, Pithavala Y. "Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)". Blood. 2004; 104:502A.
    34. Stopeck A, Iannone M, Rimsza L, Miller T, Fisher R, Bellamy W. "Expression of VEGF, VEGF receptors and other angiogenic markers in relapsed aggressive NHL: correlative studies from SWOG S0 108 trial". Blood. 2004; 104:629A.
    35. List A F, Kurtin S, Glinsmann-Gibson B J, Bellamy W, Buresh A, Mahadevan D, Rimsza L, Waddelton D, Knight R D. "Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS)". Blood. 2003; 102:184A.
    36. Bellamy W. Angiopoietin expression in multiple myeloma. Blood. 2003; 102:417-418.
    37. Bellamy WT. Vascular endothelial growth factor as a target opportunity in hematological malignancies. Curr Opin Oncol. 2002; 14(6):649 - 656.
    38. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002; 62(17):5089 - 5095.
    39. List A F, Kurtin S E, Callander N, Anderson J E, Foran J M, Rabinowitz, Glinsmann-Gibson B J, Bellamy W, Bennett J M, Collier M. "Randomized, double-blind phase II study of the matrix metalloproteinase (MMP) inhibitor, AG3340 (Prinomastat TM) in patients with myelodysplastic syndrome (MDS)". Blood. 2002; 100:789A.
    40. List A F, Kurtin S E, Glinsmann-Gibson B J, Bellamy W, Buresh A J, Waddleton D, Knight R. "High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS)". Blood. 2002; 100:96A.
    41. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001; 97(5):1427 - 1434.
    42. Baker, A F, Bellamy W, Glinsmann-Gibson B, Heaton R, Buresh A, Grogan T M, List A F. "Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance". Blood. 2001; 98:353-354.
    43. Welsh S J, Williams R, Bellamy W, Powis G. "Thioredoxin-1 stimulation of HIF-la and VEGF production by cancer cells and inhibition by the redox anticancer drug PX12". Proc AACR-EORTC. 2001; 7(supp): 3747S.
    44. Bellamy W, TM Grogan, AF List. Expression of VEGF in myelodysplasia. Blood. 2001; 102:1272-1273.
    45. Sepulveda RT, Jiang S, Beischel J, Bellamy WT, Watson RR. Cocaine injection and coxsackievirus B3 infection increase heart disease during murine AIDS. J Acquir Immune Defic Syndr. 2000; 25 Suppl 1:S19 - S26.
    46. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol. 2000; 31(4):475 - 481.
    47. List A F, Glinsmann-Gibson B, Stadheim C, Meuillet E, Bellamy W, Powis G. "VEGFR1 and VEGFR2 ligation stimulate phosphoinositide-3-kinase dependent Akt activation and promote proliferation of AML cells". Blood. 2000; 96:301A.
    48. Martinez-Zaguilan R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999; 57(9):1037 - 1046.
    49. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999; 59(3):728 - 733.
    50. Beischel J, Bellamy W, Larson D F, Watson R R. "Increased intracardiac vascular density and expression of vascular endothelial growth factor in mice infected with the HIV-model virus LP-BM5". FASEB J. 1999; 13:A38.
    51. Bellamy W, Richter L, Frutiger Y, Roxas C, Sirjani D, Inge L, Grogan T M. "Expression of vascular endothelial cell growth factor (VEGF) and its receptors in non-Hodgkin's lymphoma". Proc Amer Assoc Cancer Res. 1999; 40:227.
    52. Bellamy W, Richter L, Frutiger Y, Sirjani D, Glinsmann-Gibson B, Grogan T M, List A F. "Vascular endothelial cell growth factor (VEGF) is an autocrine promoter of ALIP and leukemia progenitor formation". Blood. 1999; 94(supp 1):389A.
    53. Dorr RT, Bellamy W, Liddil JD, Baker A, Bair KW. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998; 13(7):825 - 835.
    54. Bellamy W, Richter L, Fruitiger Y, Bieschel J, Grogan T M. "Expression of vascular endothelial cell growth factor (VEGF) and its receptors in hematopoietic malignancies". Proc Amer Assoc Cancer Res. 1998; 39:377.
    55. Bellamy W, Parrish P, Raymond M A, Williams S K, Boswell C A. "Anti-angiogenic activity of Paclitaxel (taxol) as assessed using a novel three-dimensional in vitro assay of antiogenesis". 1997. 1997; 11:A544.
    56. Rimsza L, Vela E, Richter L, Grogan T, Bellamy W. "Assessment of kappa and lambda light chain mRNA in paraffin embedded bone marrow core biopsies and lymph nodes using automated colorimetric in situ hybridization". Mod Pathol. 1997; 10:133A.
    57. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res. 1996; 56(23):5435 - 5442.
    58. Rimsza LM, Vela EE, Frutiger YM, Richter LC, Grogan TM, Bellamy WT. Combined In Situ Hybridization and Immunohistochemistry for Automated Detection of Cytomegalovirus and p53. Mol Diagn. 1996; 1(4):291 - 296.
    59. Rimsza LM, Vela EE, Frutiger YM, Rangel CS, Solano M, Richter LC, Grogan TM, Bellamy WT. Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsies. Am J Clin Pathol. 1996; 106(4):544 - 548.
    60. Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996; 36:161 - 183.
    61. Bellamy W. Annual Review of Pharmacology and Toxicology, Volume 36. P-glycoproteins and Multidrug resistance. 1996.
    62. Rimsza L, Vela E, Frutiger Y, Rangel C, Richter L, Bellamy W, Grogan TM. "Combined automated in situ hybridization and immunohistochemistry for rapid automated detection of cytomegalovirus RNA and protein". Mod Path. 1996; 9:174A.
    63. Bellamy W. Mechanisms and Reversal of Multidrug Resistance in Cancer. The Role of Glutathione s-Transferases in Drug Resistance. 1995.
    64. Snodgrass D, Mendibles P, Crowley C, Bellamy W. "The selection and characterization of a mitoxantrone-resistant human KB carcinoma cell line". Proc Amer Assoc Cancer Res. 1995; 36:1891.
    65. Bellamy W, Rimsza L, Odeleye A, Clapick S, Weinstein R S, Grogan T M. "Development and utilization of two in vivo models of multidrug resistant human myeloma in the SCID mouse". FASEB Journal. 1995; 9:5617.
    66. TM Grogan, C Rangel, L Rimsza, Bellamy W, R Martel, D McDaniel, B McGraw, W Richards, L Richter, P Rodgers, J Rybski, W Showalter, E Vela, R Zehab. Advances in Pathology and Laboratory Medicine, Volume 8. Kinetic-mode automated double labeled immunohistochemistry and in situ hybridization in diagnostic pathology. 1995.
    67. Bellamy W, T Grogan, R Weinstein. Human Cancer Markers, Volume 2. P-glycoproteins in Tumors. 1995.
    68. Bellamy W, Weinstein RS. Functional diversity in the multidrug resistance gene family. Lab Invest. 1994; 71(5):617 - 620.
    69. Bellamy W, Peng Y, Odeleye A, Huizenga E, Xu M, Grogan T, Weinstein R. "The addition of cyclosporin A results in markedly elevated tissue levels of doxorubicin in the SCID mouse". Proc Amer Accos Cancer Res. 1994; 35:354.
    70. Bellamy W, W Dalton. Advances in Clinical Chemistry, Volume 31. Multidrug Resistance in the Laboratory and Clinic. 1994.
    71. Bellamy W, Odeleye A, Finley P, Huizenga E, Dalton W, Weinstein R S, Grogan T M. "An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mouse". Anticancer Drugs. 1994; 5 (supp 1):16.
    72. Bellamy W, RS Weinstein. Functional Diversity in the Multidrug Resistance Gene Family. Lab Invest. 1994; 71:617-620.
    73. Bellamy W, Peng Y, Odeleye A, Huizenga E, Xu M, Grogan T, Weinstein R. "The addition of cyclosporin A results in markedly elevated tissue levels of doxorubicin in the SCID mouse". Anticancer Drugs. 1994; 5 (supp 1):22.
    74. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem. 1994; 31:1 - 61.
    75. Bellamy W, Bonjte P, Mendibles P, Thompson F, Richter L, Odeleye A, Weinstein R, Grogan T. "Development and characterization of doxorubicin and mitoxantrone resistant human multiple myeloma cell lines expressing the P-glycoprotein". Proc Amer Assoc Cancer Res. 1994; 35:343.
    76. Bellamy W, Odeleye A, Finley P, Huizenga B, Weinstein R, Grogan T. "An in vivo model of chemosensitization of multidrug resistant human myeloma cell lines in SCID mice". Proc Amer Assoc Cancer Res. 1993; 34:319.
    77. Bellamy W. Advances in Pathology and Laboratory Medicine, Volume 6. Chemosensitivity Testing in Human Cancer. 1993.
    78. Bellamy W. "Non-P-glycoprotein mediated multiple drug resistance in a human breast cancer cell line". Proc Amer Assoc Cancer Res. 1993; 34:305.
    79. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs. 1992; 44(5):690 - 708.
    80. Bellamy W, Odeleye A, Finley P, Grogan T. "An in vivo model of chemotherapy and chemosensitization of multidrug resistant human myeloma cell line in mice with severe combined immune deficiency". Proc Amer Assoc Cancer Res. 1992; 33:485.
    81. Payne C, Bellamy W, North J, Bjore Jr C, Weinstein R. "Quantitative electron microscopic analysis of surface negative charge on multidrug resistant and sensitive breast carcinoma cell lines". Proc Amer Assoc Cancer Res. 1992; 33:474.
    82. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer. 1991; 63(6):923 - 929.
    83. Bellamy W, Gleason M, Dalton W. "Altered P-glycoprotein mediated doxorbumicin resistance i na verapamil resistant human multiple myeloma cell line". Proc Amer Assoc Cancer Res. 1991; 32: 367.
    84. Bellamy WT. Multidrug resistance in human tumors. Curr Opin Oncol. 1990; 2(6):1126 - 1132.
    85. Bellamy W, Dalton W, Gleason M, Meltzer P, Spier C, Sullivan D. "Develment of a doxorubicin and verapamil resistant human myeloma cell line". Proc Amer Assoc Cancer Res. 1990; 31:364.
    86. Parrish P, Cress A, Gleason M, Bellamy W, Dalton W. "Enhanced drug efflux in mitoxantrone resistant human cells is not attributed to P-glycoprotein". Proc Amer Assoc Cancer Res. 1990; 31:378.
    87. Schepper R, Dalton W, Grogan T, Taylor C, Scuderi P, Bellamy W, Schlosser A. "Human multidrug-resistant cells display undiminshed sensitivity to both NK and LAK cell-mediated cytotoxicity". Proc Amer Soc Cancer Res. 1990; 31:272.
    88. Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of multidrug resistance. Cancer Invest. 1990; 8(5):547 - 562.
    89. Bellamy W, Dorr R, Bair K, Alberts D. "Cytotoxicity and mechanism of action of three arylmethylaminopropanediols (AMAPS)". Proc Amer Assoc Cancer Res. 1989; 30:562.
    90. Gleason M, Bellamy W, Dalton W. "Development of a melphalan drug resistant human myeloma cell line". Amer Soc Clin Oncol. 1989; 8:251.
    91. Bellamy WT, Dorr RT, Dalton WS, Alberts DS. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res. 1988; 48(22):6360 - 6364.
    92. Bellamy WT, Alberts DS, Dorr RT. Daily variation in non-protein sulfhydryl levels of human bone marrow. Eur J Cancer Clin Oncol. 1988; 24(11):1759 - 1762.
    93. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988; 48(22):6365 - 6370.
    94. Bellamy W. Mechanisms of Doxorubicin Resistance in Human Myeloma Cells. 1988.
    95. Bellamy W, Dorr R, Dalton W, Meltzer P, Alberts D. "The role of glutathione as a potential detoxification system in multidrug resistnat human myeloma cells". Proc Amer Assoc Cancer Res. 1988; 29:317.
    96. Bellamy W, Dorr R. "The role of glutathione in multidrug resistant human myeloma cells". Toxicol. 1988; 8:236.
    97. Bellamy W, Dorr R, Russel D, Dalton W. "Does drug accumulation entirely explain the phenomenon of multidrug resistance?". Proc Amer Assoc Cancer Res. 1987; 28:276.
    98. Taylor C, Dalton W, Bellamy W, Dorr R, Cress A. "Biochemical effects of hyperthermia on a doxurubicin resistant human myeloma cell line". 1987; 28:276.
    99. Bellamy W, Carter D E. "Urinary porphyrins as a measure of arsenic exposure in the rat". 1986; 6:21.
    100. Rodeheaver GT, Kurtz LD, Bellamy WT, Smith SL, Farris H, Edlich RF. Biocidal braided sutures. Arch Surg. 1983; 118(3):322 - 327.
    101. Herold DA, Rodeheaver GT, Bellamy WT, Fitton LA, Bruns DE, Edlich RF. Toxicity of topical polyethylene glycol. Toxicol Appl Pharmacol. 1982; 65(2):329 - 335.
    102. Rodeheaver G, Bellamy W, Kody M, Spatafora G, Fitton L, Leyden K, Edlich R. Bactericidal activity and toxicity of iodine-containing solutions in wounds. Arch Surg. 1982; 117(2):181 - 186.
    103. Bellamy W. "Vascular endothelial growth factor (VEGF) in myeloma angiogenesis".
    104. Grogan T M, Richter L, Vela L, Bellamy W. "In situ hybridization (ISH) for detection of viral antigens in B-cell lymphomas".
    105. List A F, Grogan T M, Bellamy W. "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies".
    106. Bellamy W. "Expression of VEGF in multiple myeloma".
    107. Bellamy W, Carter DE. "Distribution of arsenic after intratracheal gallium arsenide administration in the hamster".
    108. Rimsza L, Vela E, Frutiger Y, Rangel C, Richter L, Bellamy W, Grogan T M. "Combined in situ hybridization and immunohistochemistry for automated detection of mRNA (cytomegalovirus) and protein (p53)".
    109. Bellamy W, Frutiger Y, Grogan T M, Rimsza L, Iannone M, Stopeck A. "Expression of vascular endothelial cell growth factor (VEGF) and its receptors in non-Hodgkin's Lymphoma (NHL)". Frontiers in Biomedical Research Symposium.
    Bellamy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _